Core Viewpoint - The article emphasizes Haier Biomedical's unique approach in the life sciences tools industry, focusing on building an ecosystem of interdependent new industries rather than just excelling in a single niche. This strategic shift is reflected in the company's financial performance and growth trajectory [1][3]. Financial Performance - In 2022, Haier Biomedical achieved a revenue of 2.33 billion yuan, marking a 2.0% year-on-year growth. Notably, revenue from new industries, including smart medication, blood technology, and laboratory solutions, accounted for 48.5% of total revenue, nearing half of the overall income [1][3]. - The proportion of new industry revenue increased from 38% in 2023 to 48.5% in 2025, representing an over 10 percentage point rise, indicating that new industries have evolved from exploratory growth points to core engines driving the company's performance [3]. Business Model Transformation - The transformation in Haier Biomedical's business model is highlighted through its smart medication solutions, which have significantly improved efficiency in hospital pharmacies, increasing dispensing efficiency by over 40% and reducing patient wait times [4]. - The company has shifted its value proposition from "product functionality" to "user efficiency" and "scene experience," enhancing customer loyalty and the value contribution per user [4]. Blood Technology and Laboratory Solutions - Haier Biomedical has captured over 50% of the domestic market share for plasma collection solutions, evolving its business model to a comprehensive service framework that includes smart devices, consumables, software platforms, and value-added services [5]. - The laboratory segment has shown resilience, with the company maintaining leading market shares in key product lines, such as organic carbon analyzers and biological safety cabinets [6]. Global Market Expansion - By 2025, Haier Biomedical's overseas revenue reached 840 million yuan, a 17.9% increase, accounting for 36% of main revenue, with double-digit growth across Europe, Asia-Pacific, and the Americas [6]. - The company successfully exported its smart medication solutions to Southeast Asia and the Middle East, demonstrating the quality of its overseas growth [6]. AI and Research Integration - The integration of AI into Haier Biomedical's operations has evolved from a supportive tool to a strategic core, contributing 15% to overall revenue by 2025, up 2.5 percentage points from the previous year [8]. - The company has established a multi-layered AI infrastructure that enhances efficiency in research and development, leading to a 6% reduction in new product development cycles and a 40% increase in patent filings [8]. Future Outlook - Haier Biomedical is positioned at the beginning of a "quality dividend" phase, with new factories overcoming capacity ramp-up periods and innovative products entering the market [12][13]. - The company aims to increase its overseas revenue share to 50% and new industry revenue to 50% within three years, indicating a commitment to global expansion and high-quality growth [13].

Group 1 - The core viewpoint emphasizes the integration of AI in various research fields, showcasing significant advancements in industrial software development and ancient biology research [1][2] - The Nanjing Guorui Xinwei Software Company has developed over 20 proprietary industrial software products, raising nearly 600 million yuan for technological innovation and product upgrades [1] - AI algorithms have drastically reduced the time and cost of reconstructing ancient biological fossils, improving efficiency and experimental throughput [1][2] Group 2 - Collaboration between AI teams and traditional research teams is driven by project-based mechanisms, including cross-disciplinary project groups and internal AI training [2] - AI applications in oil and gas research have automated traditional processes, significantly reducing the time required for geological profiling from one year to one month [2] Group 3 - The government is expected to establish platforms for data security, shared pilot testing bases, and provide continuous funding support to facilitate the industrial transformation of AI research [3] - In ancient biology, there is a need for shared AI infrastructure and interdisciplinary talent cultivation to better integrate AI with research demands [3] Group 4 - AI technologies have enhanced the autonomous decision-making and anti-jamming capabilities of radar systems, with applications in complex signal environments [4] - The establishment of a geological biodiversity database has addressed the data supply-demand contradiction in ancient biology, supporting AI applications [4] Group 5 - The focus is on deeply integrating AI into the entire equipment development process, exploring the application of intelligent agents for optimized design and production scheduling [5][6] - AI is expected to transform ancient biology research from qualitative descriptions to quantitative analyses, with ongoing projects aimed at high-precision geological mapping [6]

Group 1 - The AI4S Innovation Forum was held in Beijing, focusing on the integration of AI in scientific research, particularly in chemical materials and biomedicine [1][3] - The launch of the AI for Science platform aims to enhance research efficiency and lower barriers for research institutions and enterprises [1][3] - The AI + New Materials Joint Laboratory was officially established to promote the development and industrial application of new materials, fostering interdisciplinary talent [1][3] Group 2 - The CEO of Fengqing Technology, Gao Xuefeng, emphasized the importance of integrating AI with scientific research to create a new paradigm for innovation [3][6] - The AI for Science platform is designed to enhance the original innovation efficiency and result transformation speed of the national research system [6] - Fengqing Technology is committed to building a new generation of intelligent platforms that enhance the precision and interpretability of scientific innovation [6]